| Literature DB >> 28811270 |
Ran A Cai1, Dominik Beste2, Hema Chaplin1, Socrates Varakliotis2, Linda Suffield1, Francesca Josephs1, Debajit Sen1,3, Lucy R Wedderburn1,4, Yiannakis Ioannou1,3, Stephen Hailes2, Despina Eleftheriou1,4.
Abstract
BACKGROUND: Flare-ups in juvenile idiopathic arthritis (JIA) are characterized by joint pain and swelling and often accompanied with fatigue, negative emotions, and reduced participation in activities. To minimize the impact of JIA on the physical and psychosocial development and well-being of young people (YP), it is essential to regularly monitor disease activity and side effects, as well as to support self-management such as adherence to treatment plans and engagement in general health-promoting behaviors. Smartphone technology has the potential to engage YP with their health care through convenient self-monitoring and easy access to information. In addition, having a more accurate summary of self-reported fluctuations in symptoms, behaviors, and psychosocial problems can help both YP and health care professionals (HCPs) better understand the patient's condition, identify barriers to self-management, and assess treatment effectiveness and additional health care needs. No comprehensive smartphone app has yet been developed in collaboration with YP with JIA, their parents, and HCPs involved in their care.Entities:
Keywords: adolescent; juvenile idiopathic arthritis; mobile applications; qualitative research; self-management; smartphone; young adult
Year: 2017 PMID: 28811270 PMCID: PMC5575419 DOI: 10.2196/mhealth.7229
Source DB: PubMed Journal: JMIR Mhealth Uhealth ISSN: 2291-5222 Impact factor: 4.773
Patient baseline characteristics, disease duration, and treatment received.
| Phase | Patient ID | Age, in years | Gender | JIAa subclassification | Disease duration, in years | Current medication |
| I | 1 | 21 | F | Persistent oligoarticular JIA | 17 | Nil. Previously treated with intra-articular steroid injections |
| 2 | 18 | M | ERAb | 3 | Methotrexate (15 mg/m2 scc weekly) | |
| 3 | 17 | M | Persistent oligoarticular JIA | 4 | Nil. Previously treated with intra-articular steroid injections | |
| 4 | 18 | M | ERA | 7 | Etanercept (0.8 mg/kg sc weekly) and methotrexate (15 mg/m2 sc weekly) | |
| 5 | 18 | F | Polyarticular JIA | 15 | Methotrexate (15 mg/m2 sc weekly) and adalimumab (40 mg sc fortnightly) | |
| 6 | 10 | M | Extended oligoarticular JIA | 4 | Methotrexate (15 mg/m2 sc weekly) | |
| 7 | 14 | F | Systemic JIA | 3 | Methotrexate (15 mg/m2 sc weekly) | |
| 8 | 12 | M | Extended oligoarticular JIA | 7 | Nil. Previously treated with intra-articular steroid injections | |
| 9 | 11 | M | Systemic JIA | 2 | Tocilizumab (8 mg/kg fortnightly) and methotrexate (15 mg/m2 sc weekly) | |
| 10 | 12 | F | Psoriatic arthritis | 0.4 | Methotrexate (15 mg/m2 sc weekly) | |
| II | 2 | 18 | M | ERA | 3 | Methotrexate (20 mg/m2 sc weekly) and humira (40 mg sc weekly) |
| 6 | 10 | M | Extended oligoarticular JIA | 5 | Methotrexate (15 mg/m2 sc weekly) | |
| 7 | 14 | F | Systemic JIA | 3 | Methotrexate (15 mg/m2 sc weekly) | |
| 8 | 12 | M | Extended oligoarticular JIA | 7 | Nil | |
| 9 | 12 | M | Systemic JIA | 3 | Tocilizumab (8 mg/kg fortnightly) and methotrexate (15 mg/m2 sc weekly) | |
| 10 | 13 | F | Psoriatic arthritis | 0.8 | Methotrexate (15 mg/m2 sc weekly) | |
| 11 | 23 | F | Bilateral inflammatory hip arthritis | 11 | Methotrexate (10 mg/m2 sc weekly) | |
| 12 | 17 | F | Systemic JIA | 2 | Hydroxychloroquine (400 mg orally daily) | |
| 13 | 20 | F | Persistent oligoarticular JIA | 5 | Methotrexate (20 mg orally weekly) | |
| 14 | 16 | F | Extended oligoarticular JIA | 14 | Methotrexate (15 mg/m2 sc weekly) | |
| 15 | 17 | F | Polyarticular JIA | 9 | Etanercept (25 mg sc weekly) | |
| 16 | 14 | F | Psoriatic arthritis | 12 | Adalimumab (40 mg sc fortnightly) | |
| 17 | 12 | F | Persistent oligoarticular JIA | 8 | Methotrexate (15 mg/m2 sc weekly) | |
| III | 4 | 18 | M | ERA | 8 | Methotrexate (15 mg/m2 sc weekly) |
| 18 | 16 | F | Oligoarticular JIA | 12 | Nil | |
| 19 | 12 | M | Polyarticular JIA | 4 | Methotrexate (25 mg orally weekly) | |
| 20 | 14 | F | Psoriatic arthritis | 8 | Methotrexate (12.5 mg/m2 sc weekly) | |
| 21 | 15 | M | Extended oligoarticular JIA | 8 | Naproxen (500 mg twice a day) | |
| 22 | 17 | F | Extended oligoarticular JIA | 15 | Methotrexate (15 mg/m2 sc weekly) and folic acid (5 mg orally weekly) | |
| 23 | 13 | F | Oligoarticular JIA | 10 | Methotrexate (15 mg/m2 sc weekly) and humira (40 mg fortnightly) | |
| 24 | 15 | F | Systemic JIA | 3 | Methotrexate (27.5 mg/m2 sc weekly), anakinra (150 mg sc daily), and folic acid (5 mg orally weekly) | |
| 25 | 15 | F | Oligoarticular JIA | 4 | Nil | |
| 26 | 23 | M | Extended oligoarticular JIA | 21 | Keppra (500 mg twice a day) | |
| 27 | 15 | F | ERA | 3 | Methotrexate (15 mg/m2 sc weekly) and folic acid (5 mg orally weekly) | |
| 28 | 16 | M | Polyarticular JIA | 1 | Methotrexate (15 mg orally weekly) and folic acid (5 mg orally weekly) | |
| 29 | 18 | F | Polyarticular JIA | 2 | Enbrel (50 mg sc weekly) and methotrexate (7.5 mg orally weekly) |
aJIA: juvenile idiopathic arthritis.
bERA: enthesitis-related arthritis.
csc: subcutaneously.
Figure 1Study phases and iterative development cycle.
Figure 2Results of content analysis of transcripts from focus groups for phase I.
Figure 3Screenshots of the app for monitoring symptoms, thoughts, & feelings.
Figure 4Screenshots of the app for adherence and information.
Figure 5Results of content analysis of transcripts from focus groups for phase II.
Applying the Capability, Opportunity, Motivation-Behavior (COM-B) model to major themes identified for JIApp.
| Themes | Capability | Opportunity | Motivation |
| Theme 1: | Self-awareness and understanding patterns | Perception of illness and self-efficacy | |
| Better patient-clinician communication | |||
| Theme 2: Treatment adherence | Reminders for treatment adherence | Recording past adherence can stimulate action | |
| Theme 3: Education and support | Knowledge of juvenile idiopathic arthritis and treatments | Confidence in skills and empowerment | |
| Knowledge of self-management skills and emotion regulation | |||
| Theme 4: Incentives | Expectation of rewards | ||
| Theme 5: Design of user interface | Convenient monitoring | ||
| Convenient access to reliable information and support |
Figure 6JIApp system.